Clarivate notched a fifth consecutive EPS beat on disciplined cost management, though revenue missed as the information services company sheds its Life Sciences segment and races to swap transactional business for recurring subscriptions. The company reaffirmed full-year guidance and expects organic recurring revenue growth to accelerate by over 100 basis points in the second half as AI-native products like Web of Science Research Intelligence gain traction.
Clarivate :
CLVT
CLVT
Stock Data
$1.88
$0.02 (0.81%)
Asset Type
Common Stock
Exchange
NYSE
Currency
USD
Country
USA
Sector
TECHNOLOGY
Industry
INFORMATION TECHNOLOGY SERVICES
Clarivate Plc is a global information services provider, delivering critical data and insights across various sectors including academia, government, life sciences, healthcare, and intellectual property. With a rich history dating back to 1864, Clarivate offers a suite of products like Web of Science, ProQuest, and Cortellis, aimed at enhancing research, supporting patent and trademark processes, and facilitating drug development. Headquartered in London, it serves a diverse clientele including corporations, universities, and government agencies, helping them navigate the complexities of innovation and regulatory compliance.
Latest Activity
All Clarivate Articles
2 Articles